公司概述
Intensity Therapeutics, Inc. operates as a late-stage clinical biotechnology company dedicated to developing treatments for the regional and systemic manifestations of cancer within the United States market. The firm functions within the broader Healthcare sector, specifically focusing on the Biotechnology industry, which implies a high-risk, high-reward environment characterized by significant research and development expenditures prior to commercial product approval. As of the latest data, the company holds a market capitalization of $14.23 million and employs a staff of 5 individuals, reflecting a very early-stage organizational scale typical of pre-revenue biotech entities. This limited market cap and absence of reported revenue indicate that the company is currently in a development phase where its primary value proposition relies on the potential future success of its clinical pipeline, specifically its lead product candidate INT230-6, rather than current operational cash flows.
财务健康
The financial statements reveal a net income of -$11,606,000 for the trailing twelve months, with revenue and EBITDA figures listed as N/A, highlighting that the company has not yet achieved commercial profitability. The substantial gap between revenue and net income, in the absence of reported revenue, underscores a cost structure entirely driven by operational and research expenses rather than sales deductions. Free cash flow stands at -$5,109,500, indicating that the company is consuming cash to fund its operations and clinical trials, which limits its immediate financial flexibility and reliance on external capital markets. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a standard presentation for companies with negligible or unreported revenue that has not yet crossed the threshold to calculate meaningful percentage margins. On the balance sheet, the company holds $11.92 million in cash against a debt level of $110,000, creating a significantly conservative liquidity position with a debt-to-equity ratio of 0.93. The current ratio of 5.92 suggests a robust ability to meet short-term obligations, although this metric is less relevant given the lack of revenue generation. Return on Equity is -156.9% and Return on Assets is -79.2%, metrics that reflect the dilution of shareholder value and asset efficiency typical of early-stage biotechs burning cash to advance clinical studies.
估值评估
The valuation metrics present a challenging picture, with a P/E Ratio (TTM) listed as N/A due to negative earnings, while the Forward P/E is calculated at -1.40, implying that the market does not expect immediate positive earnings turnaround in the near future. The Price to Book ratio is 1.19, suggesting the company trades at a slight premium to its book value, which can be attributed to the intangible value of its clinical pipeline assets rather than tangible operational history. Alternative valuation metrics such as Price to Sales and EV/EBITDA are both N/A, further confirming that traditional multiples are not applicable to a company without established sales or positive operating earnings. The stock's price range over the past year has been highly volatile, oscillating between a 52-week low of $4.62 and a 52-week high of $50.00. Given the wide dispersion between these extremes, the current trading price is significantly below the 52-week high, reflecting the market's caution regarding the high uncertainty of clinical trial outcomes. The Beta of 4.23 indicates extreme price volatility, meaning the stock's price swings are more than four times greater than the broader market, exposing investors to substantial short-term risk.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, as the company has not yet generated sufficient revenue to calculate year-over-year growth rates or establish a historical earnings baseline for comparison. Consequently, the analysis of whether earnings are growing faster or slower than revenue is not applicable in the traditional sense, as both metrics are currently undefined. As a non-dividend payer, the company offers a Dividend Yield of N/A with a Payout Ratio of 0.0%, indicating that all available cash flow is theoretically available for reinvestment into growth initiatives rather than being distributed to shareholders. The overall growth and income profile is characterized by a complete reliance on capital appreciation potential and the successful progression of its clinical programs, rather than income generation or historical sales expansion.